Rapamycin: An InhibiTOR of aging emerges from the soil of Easter island

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 71, Issue 7, 2016, Pages 841-849

  Arriola Apelo, Sebastian I ^a   Lamming, Dudley W ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Intermittent rapamycin; Lifespan; Mouse; Rapamycin analogs

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

AGING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DESIGN; DRUG EFFECTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMAN; LONGEVITY; METABOLISM; MOUSE; PHYSIOLOGY;

AGING; ANIMALS; DRUG DESIGN; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONGEVITY; MICE; MULTIPROTEIN COMPLEXES; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84979233554     PISSN: 10795006     EISSN: 1758535X     Source Type: Journal    
DOI: 10.1093/gerona/glw090     Document Type: Review

References (126)

1. Vézina C, Kudelski A, Sehgal SN. Rapamycin (AY-22, 989), a new antifungal antibiotic: I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo). 1975;28:721-726.
2. Martel RR, Klicius J, Galet S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol. 1977;55: 48-51.
3. Dumont FJ, Staruch MJ, Koprak SL, Melino MR, Sigal NH. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol. 1990;144:251-258.
4. Singh K, Sun S, Vézina C. Rapamycin (AY-22, 989), a new antifungal antibiotic II. Mechanism of action. J Antibiot. 1979;32:630-645.
5. Kino T, Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces II. Immunosuppressive effect of FK-506 in vitro. J Antibiot. 1987;40:1256-1265.
6. Fruman DA, Klee CB, Bierer BE, Burakoff SJ. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci USA. 1992;89:3686-3690. doi: 10.1073/pnas.89.9.3686
7. O'Keefe SJ, Tamura J, Kincaid RL, Tocci MJ, O'Neill EA. FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. Nature. 1992;357:692-694.
8. Lamming DW, Sabatini DM. Regulation of TOR signaling in mammals. Enzymes. 2010;27:21-38. doi: 10.1016/s1874-6047(10)27002-6
9. Caron A, Richard D, Laplante M. The roles of mTOR complexes in lipid metabolism. Annu Rev Nutr. 2015;35:321-348. doi: 10.1146/annurevnutr- 071714-034355
10. Lamming DW. Diminished mTOR signaling: a common mode of action for endocrine longevity factors. Springerplus. 2014;3:735. doi: 10.1186/2193- 1801-3-735
11. Bar-Peled L, Sabatini DM. Regulation of mTORC1 by amino acids. Trends Cell Biol. 2014;24:400-406. doi: 10.1016/j.tcb.2014.03.003
12. Chantranupong L, Wolfson RL, Sabatini DM. Nutrient-sensing mechanisms across evolution. Cell. 2015;161:67-83. doi: 10.1016/j.cell.2015.02.041
13. Wolfson RL, Chantranupong L, Saxton RA, et al. Sestrin2 is a leucine sensor for the mTORC1 pathway. Science. 2016;351:43-48. doi: 10.1126/science.aab2674
14. Chantranupong L, Scaria SM, Saxton RA, et al. The CASTOR proteins are arginine sensors for the mTORC1 pathway. Cell. 2016;165:153-164. doi: 10.1016/j.cell.2016.02.035
15. Wang S, Tsun ZY, Wolfson RL, et al. Metabolism. Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1. Science. 2015;347:188-194. doi: 10.1126/science.1257132
16. Rebsamen M, Pochini L, Stasyk T, et al. SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1. Nature. 2015;519:477-481. doi: 10.1038/nature14107
17. Lamming DW, Ye L, Katajisto P, et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science. 2012;335:1638-1643. doi: 10.1126/science.1215135
18. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006;22:159-168. doi: 10.1016/j.molcel.2006.03.029
19. Schreiber KH, Ortiz D, Academia EC, Anies AC, Liao CY, Kennedy BK. Rapamycin-mediated mTORC2 inhibition is determined by the relative expression of FK506-binding proteins. Aging Cell. 2015;14:265-273. doi: 10.1111/acel.12313
20. Houchens DP, Ovejera AA, Riblet SM, Slagel DE. Human brain tumor xenografts in nude mice as a chemotherapy model. Eur J Cancer Clin Oncol. 1983;19:799-805. doi:http://dx.doi.org/10.1016/0277-5379(83) 90012-3
21. Eng CP, Sehgal SN, Vezina C. Activity of rapamycin (AY-22, 989) against transplanted tumors. J Antibiot. 1984;37:1231-1237.
22. Kaeberlein M, Powers RW 3rd, Steffen KK, et al. Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients. Science. 2005;310:1193-1196. doi: 10.1126/science.1115535
23. Vellai T, Takacs-Vellai K, Zhang Y, Kovacs AL, Orosz L, Müller F. Genetics: influence of TOR kinase on lifespan in C. elegans. Nature. 2003;426:620. doi: 10.1038/426620a
24. Bjedov I, Toivonen JM, Kerr F, et al. Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster. Cell Metab. 2010;11:35-46. doi: 10.1016/j.cmet.2009.11.010
25. Powers RW 3rd, Kaeberlein M, Caldwell SD, Kennedy BK, Fields S. Extension of chronological life span in yeast by decreased TOR pathway signaling. Genes Dev. 2006;20:174-184. doi: 10.1101/gad.1381406
26. Medvedik O, Lamming DW, Kim KD, Sinclair DA. MSN2 and MSN4 link calorie restriction and TOR to sirtuin-mediated lifespan extension in Saccharomyces cerevisiae. PLoS Biol. 2007;5:e261. doi: 10.1371/journal.pbio.0050261.
27. Robida-Stubbs S, Glover-Cutter K, Lamming DW, et al. TOR signaling and rapamycin influence longevity by regulating SKN-1/Nrf and DAF-16/FoxO. Cell Metab. 2012;15:713-724. doi: 10.1016/j.cmet.2012.04.007
28. Ha CW, Huh WK. Rapamycin increases rDNA stability by enhancing association of Sir2 with rDNA in Saccharomyces cerevisiae. Nucleic Acids Res. 2011;39:1336-1350. doi: 10.1093/nar/gkq895
29. Majumder S, Caccamo A, Medina DX, et al. Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL- 1beta and enhancing NMDA signaling. Aging Cell. 2012;11:326-335. doi: 10.1111/j.1474-9726.2011.00791.x
30. Spilman P, Podlutskaya N, Hart MJ, et al. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS One. 2010;5:e9979. doi: 10.1371/journal.pone.0009979
31. Dai DF, Karunadharma PP, Chiao YA, et al. Altered proteome turnover and remodeling by short-term caloric restriction or rapamycin rejuvenate the aging heart. Aging Cell. 2014;13:529-539. doi: 10.1111/acel.12203
32. Ozcelik S, Fraser G, Castets P, et al. Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice. PLoS One. 2013;8:e62459. doi: 10.1371/journal.pone.0062459
33. Wilkinson JE, Burmeister L, Brooks SV, et al. Rapamycin slows aging in mice. Aging Cell. 2012;11:675-682. doi: 10.1111/j.1474-9726.2012.00832.x
34. Lin AL, Jahrling JB, Zhang W, et al. Rapamycin rescues vascular, metabolic and learning deficits in apolipoprotein E4 transgenic mice with pre-symptomatic Alzheimer's disease. J Cereb Blood Flow Metab. 2015. doi: 10.117 7/0271678X15621575
35. Bai X, Wey MC, Fernandez E, et al. Rapamycin improves motor function, reduces 4-hydroxynonenal adducted protein in brain, and attenuates synaptic injury in a mouse model of synucleinopathy. Pathobiol Aging Age Relat Dis. 2015;5:28743. doi: 10.3402/pba.v5.28743
36. Grabiner BC, Nardi V, Birsoy K, et al. A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. Cancer Discov. 2014;4:554-563. doi: 10.1158/2159-8290.CD-13-0929
37. Wagle N, Grabiner BC, Van Allen EM, et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 2014;4:546-553. doi: 10.1158/2159-8290.CD-13-0353
38. Neff F, Flores-Dominguez D, Ryan DP, et al. Rapamycin extends murine lifespan but has limited effects on aging. J Clin Invest. 2013;123:3272-3291. doi: 10.1172/JCI67674
39. Chen C, Liu Y, Liu Y, Zheng P. mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. Sci Signal. 2009;2:ra75. doi: 10.1126/scisignal.2000559
40. Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460:392-395. doi: 10.1038/nature08221
41. Miller RA, Harrison DE, Astle CM, et al. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci. 2011;66:191-201. doi: 10.1093/gerona/glq178
42. Miller RA, Harrison DE, Astle CM, et al. Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell. 2014;13:468-477. doi: 10.1111/acel.12194
43. Zaseck LW, Miller RA, Brooks SV. Rapamycin attenuates age-associated changes in tibialis anterior tendon viscoelastic properties. J Gerontol A Biol Sci Med Sci. 2016. doi: 10.1093/gerona/glv307
44. Carter CS, Khamiss D, Matheny M, et al. Rapamycin versus intermittent feeding: dissociable effects on physiological and behavioral outcomes when initiated early and late in life. J Gerontol A Biol Sci Med Sci. 2015. doi: 10.1093/gerona/glu238
45. Arriola Apelo SI, Pumper CP, Baar EL, Cummings NE, Lamming DW. Intermittent administration of rapamycin extends the life span of female C57BL/6J mice. J Gerontol A Biol Sci Med Sci. 2016. doi: 10.1093/gerona/glw064
46. Yilmaz OH, Katajisto P, Lamming DW, et al. mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake. Nature. 2012;486:490-495. doi: 10.1038/nature11163
47. Fan X, Liang Q, Lian T, et al. Rapamycin preserves gut homeostasis during Drosophila aging. Oncotarget. 2015;6:35274-35283. doi: 10.18632/oncotarget.5895
48. Selman C, Tullet JM, Wieser D, et al. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science. 2009;326:140-144. doi: 10.1126/science.1177221
49. Wu JJ, Liu J, Chen EB, et al. Increased mammalian lifespan and a segmental and tissue-specific slowing of aging after genetic reduction of mTOR expression. Cell Rep. 2013;4:913-920. doi: 10.1016/j.celrep.2013.07.030
50. Sengupta S, Peterson TR, Laplante M, Oh S, Sabatini DM. mTORC1 controls fasting-induced ketogenesis and its modulation by ageing. Nature. 2010;468:1100-1104. doi: 10.1038/nature09584
51. Tsai S, Sitzmann JM, Dastidar SG, et al. Muscle-specific 4E-BP1 signaling activation improves metabolic parameters during aging and obesity. J Clin Invest. 2015;125:2952-2964. doi: 10.1172/JCI77361
52. Dominick G, Berryman DE, List EO, et al. Regulation of mTOR activity in Snell dwarf and GH receptor gene-disrupted mice. Endocrinology. 2015;156:565-575. doi: 10.1210/en.2014-1690
53. Lebwohl D, Anak O, Sahmoud T, et al. Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases. Ann NY Acad Sci. 2013;1291:14-32. doi: 10.1111/nyas.12122
54. Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol. 2008;19:1411-1418. doi: 10.1681/ASN.2007111202
55. van Gelder T, ter Meulen CG, Hené R, Weimar W, Hoitsma A. Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation. 2003;75:788-791. doi: 10.1097/01.TP.0000056639.74982.F9
56. Sonis S, Treister N, Chawla S, Demetri G, Haluska F. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer. 2010;116:210-215. doi: 10.1002/cncr.24696
57. Felix MJ, Felipe CR, Tedesco-Silva H, Osmar Medina-Pestana J. Timedependent and immunosuppressive drug-associated adverse event profiles in de novo kidney transplant recipients converted from tacrolimus to sirolimus regimens. Pharmacotherapy. 2016;36:152-165. doi: 10.1002/phar.1692
58. Firpi RJ, Tran TT, Flores P, et al. Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent. Aliment Pharmacol Ther. 2004;19:1033-1039. doi: 10.1111/j.1365-2036.2004.01923.x
59. Cutler C, Henry NL, Magee C, et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11:551-557. doi: 10.1016/j.bbmt.2005.04.007
60. Rovira J, Diekmann F, Ramírez-Bajo MJ, Bañón-Maneus E, Moya-Rull D, Campistol JM. Sirolimus-associated testicular toxicity: detrimental but reversible. Transplantation. 2012;93:874-879. doi: 10.1097/TP.0b013e31824bf1f0
61. Trelinska J, Dachowska I, Kotulska K, Fendler W, Jozwiak S, Mlynarski W. Complications of mammalian target of rapamycin inhibitor anticancer treatment among patients with tuberous sclerosis complex are common and occasionally life-threatening. Anticancer Drugs. 2015;26:437-442. doi: 10.1097/CAD.0000000000000207
62. Powell JD, Pollizzi KN, Heikamp EB, Horton MR. Regulation of immune responses by mTOR. Annu Rev Immunol. 2012;30:39-68. doi: 10.1146/annurev-immunol-020711-075024
63. Houde VP, Brule S, Festuccia WT, et al. Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes. 2010;59:1338-1348. doi: 10.2337/db09-1324
64. Teutonico A, Schena PF, Di Paolo S. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol. 2005;16:3128-3135. doi: 10.1681/ASN.2005050487
65. Cunningham JT, Rodgers JT, Arlow DH, Vazquez F, Mootha VK, Puigserver P. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature. 2007;450:736-740. doi: 10.1038/nature06322
66. Bell E, Cao X, Moibi JA, et al. Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets. Diabetes. 2003;52:2731-2739.
67. Rachdi L, Balcazar N, Osorio-Duque F, et al. Disruption of Tsc2 in pancreatic beta cells induces beta cell mass expansion and improved glucose tolerance in a TORC1-dependent manner. Proc Natl Acad Sci USA. 2008;105:9250-9255. doi: 10.1073/pnas.0803047105
68. Lamming DW, Demirkan G, Boylan JM, et al. Hepatic signaling by the mechanistic target of rapamycin complex 2 (mTORC2). FASEB J. 2014;28:300-315. doi: 10.1096/fj.13-237743
69. Cybulski N, Polak P, Auwerx J, Rüegg MA, Hall MN. mTOR complex 2 in adipose tissue negatively controls whole-body growth. Proc Natl Acad Sci USA. 2009;106:9902-9907. doi: 10.1073/pnas.0811321106
70. Kumar A, Lawrence JC Jr, Jung DY, et al. Fat cell-specific ablation of rictor in mice impairs insulin-regulated fat cell and whole-body glucose and lipid metabolism. Diabetes. 2010;59:1397-1406. doi: 10.2337/db09-1061
71. Tang Y, Wallace M, Sanchez-Gurmaches J, et al. Adipose tissue mTORC2 regulates ChREBP-driven de novo lipogenesis and hepatic glucose metabolism. Nature Commun. 2016;7:11365. doi: 10.1038/ncomms11365
72. Kumar A, Harris TE, Keller SR, Choi KM, Magnuson MA, Lawrence JC Jr. Muscle-specific deletion of rictor impairs insulin-stimulated glucose transport and enhances basal glycogen synthase activity. Mol Cell Biol. 2008;28:61-70. doi: 10.1128/MCB.01405-07
73. Kleinert M, Sylow L, Fazakerley DJ, et al. Acute mTOR inhibition induces insulin resistance and alters substrate utilization in vivo. Mol Metab. 2014;3:630-641. doi: 10.1016/j.molmet.2014.06.004
74. Gu Y, Lindner J, Kumar A, Yuan W, Magnuson MA. Rictor/mTORC2 is essential for maintaining a balance between beta-cell proliferation and cell size. Diabetes. 2011;60:827-837. doi: 10.2337/db10-1194
75. Kocalis HE, Hagan SL, George L, et al. Rictor/mTORC2 facilitates central regulation of energy and glucose homeostasis. Mol Metab. 2014;3:394-407. doi: 10.1016/j.molmet.2014.01.014
76. Caron A, Baraboi ED, Laplante M, Richard D. DEP domain-containing mTOR-interacting protein in the rat brain: distribution of expression and potential implication. J Comp Neurol. 2015;523:93-107. doi: 10.1002/cne.23668
77. Fang Y, Westbrook R, Hill C, et al. Duration of rapamycin treatment has differential effects on metabolism in mice. Cell Metab. 2013;17:456-462. doi: 10.1016/j.cmet.2013.02.008
78. Steinbaugh MJ, Sun LY, Bartke A, Miller RA. Activation of genes involved in xenobiotic metabolism is a shared signature of mouse models with extended lifespan. Am J Physiol Endocrinol Metab. 2012;303:E488-E495. doi: 10.1152/ajpendo.00110.2012
79. Haxhinasto S, Mathis D, Benoist C. The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+cells. J Exp Med. 2008;205: 565-574. doi: 10.1084/jem.20071477
80. Byles V, Covarrubias AJ, Ben-Sahra I, et al. The TSC-mTOR pathway regulates macrophage polarization. Nature Commun. 2013;4:2834. doi: 10.1038/ncomms3834
81. Goldberg EL, Smithey MJ, Lutes LK, Uhrlaub JL, Nikolich-Zugich J. Immune memory-boosting dose of rapamycin impairs macrophage vesicle acidification and curtails glycolysis in effector CD8 cells, impairing defense against acute infections. J Immunol. 2014;193:757-763. doi: 10.4049/jimmunol.1400188
82. Festuccia WT, Pouliot P, Bakan I, Sabatini DM, Laplante M. Myeloidspecific Rictor deletion induces M1 macrophage polarization and potentiates in vivo pro-inflammatory response to lipopolysaccharide. PLoS One. 2014;9:e95432. doi: 10.1371/journal.pone.0095432
83. Covarrubias AJ, Aksoylar HI, Yu J, et al. Akt-mTORC1 signaling regulates Acly to integrate metabolic input to control of macrophage activation. eLife. 2016;5. doi: 10.7554/eLife.11612
84. Selman C, Partridge L, Withers DJ. Replication of extended lifespan phenotype in mice with deletion of insulin receptor substrate 1. PLoS One. 2011;6:e16144. doi: 10.1371/journal.pone.0016144
85. Turturro A, Witt WW, Lewis S, Hass BS, Lipman RD, Hart RW. Growth curves and survival characteristics of the animals used in the Biomarkers of Aging Program. J Gerontol A Biol Sci Med Sci. 1999;54:B492-B501.
86. Cameron KM, Miwa S, Walker C, von Zglinicki T. Male mice retain a metabolic memory of improved glucose tolerance induced during adult onset, short-term dietary restriction. Longev Healthspan. 2012;1:3. doi: 10.1186/2046-2395-1-3
87. Lamming DW, Anderson RM. Metabolic Effects of Caloric Restriction. Chichester, UK: John Wiley & Sons; 2014.
88. Lamming DW, Mihaylova MM, Katajisto P, et al. Depletion of Rictor, an essential protein component of mTORC2, decreases male lifespan. Aging Cell. 2014;13:911-917. doi: 10.1111/acel.12256
89. Baar EL, Carbajal KA, Ong IM, Lamming DW. Sex- and tissue-specific changes in mTOR signaling with age in C57BL/6J mice. Aging Cell. 2016;15:155-166. doi: 10.1111/acel.12425
90. Lind MI, Zwoinska MK, Meurling S, Carlsson H, Maklakov AA. Sexspecific tradeoffs with growth and fitness following life-span extension by rapamycin in an outcrossing nematode, Caenorhabditis remanei. J Gerontol A Biol Sci Med Sci. 2015. doi: 10.1093/gerona/glv174
91. Longo VD, Fontana L. Intermittent supplementation with rapamycin as a dietary restriction mimetic. Aging. 2011;3:1039-1040.
92. Blagosklonny MV. Once again on rapamycin-induced insulin resistance and longevity: despite of or owing to. Aging. 2012;4:350-358.
93. Anisimov VN, Zabezhinski MA, Popovich IG, et al. Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle. 2011;10:4230-4236.
94. Scarpace PJ, Matheny M, Strehler KY, et al. Rapamycin normalizes serum leptin by alleviating obesity and reducing leptin synthesis in aged rats. J Gerontol A Biol Sci Med Sci. 2015. doi: 10.1093/gerona/glu230
95. Yang SB, Lee HY, Young DM, et al. Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity. J Mol Med. 2012;90:575-585. doi: 10.1007/s00109-011-0834-3
96. Liu Y, Diaz V, Fernandez E, et al. Rapamycin-induced metabolic defects are reversible in both lean and obese mice. Aging. 2014;6:742-754.
97. Bottiger Y, Sawe J, Brattstrom C, et al. Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers. Clin Pharmacol Ther. 2001;69:32-40.
98. Arriola Apelo SI, Neuman JC, Baar EL, et al. Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system. Aging Cell. 2016;15:28-38. doi: 10.1111/acel.12405
99. Leontieva OV, Paszkiewicz GM, Blagosklonny MV. Weekly administration of rapamycin improves survival and biomarkers in obese male mice on high-fat diet. Aging Cell. 2014;13:616-622. doi: 10.1111/acel.12211
100. Zhang Y, Bokov A, Gelfond J, et al. Rapamycin extends life and health in C57BL/6 mice. J Gerontol A Biol Sci Med Sci. 2014;69:119-130. doi: 10.1093/gerona/glt056
101. Lamming DW, Ye L, Sabatini DM, Baur JA. Rapalogs and mTOR inhibitors as anti-aging therapeutics. J Clin Invest. 2013;123:980-989. doi: 10.1172/JCI64099
102. Saran U, Foti M, Dufour J-F. Cellular and molecular effects of the mTOR inhibitor everolimus. Clin Sci. 2015;129:895-914. doi: 10.1042/cs20150149
103. Iacovelli R, Santoni M, Verzoni E, et al. Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature data. Clin Genitourin Cancer. 2015;13:137-141. doi: 10.1016/j.clgc.2014.07.006
104. Formica JRN, Lorber KM, Friedman AL, et al. The evolving experience using everolimus in clinical transplantation. Transplant Proc. 2004;36:S495-S499. doi: 10.1016/j.transproceed.2004.01.015
105. Vergès B, Cariou B. mTOR inhibitors and diabetes. Diabetes Res Clin Pract. 2015;110:101-108. doi: 10.1016/j.diabres.2015.09.014
106. Fiebrich HB, Siemerink EJ, Brouwers AH, et al. Everolimus induces rapid plasma glucose normalization in insulinoma patients by effects on tumor as well as normal tissues. Oncologist. 2011;16:783-787. doi: 10.1634/theoncologist.2010-0222
107. Mannick JB, Del Giudice G, Lattanzi M, et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med. 2014;6:268ra179. doi: 10.1126/scitranslmed.3009892
108. Kaeberlein M. The biology of aging: citizen scientists and their pets as a bridge between research on model organisms and human subjects. Vet Pathol. 2016;53:291-298. doi: 10.1177/0300985815591082
109. Check Hayden E. Pet dogs set to test anti-ageing drug. Nature. 2014;514:546. doi: 10.1038/514546a
110. Machka C, Lange S, Werner J, et al. Everolimus in combination with mycophenolate mofetil as pre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermates. Biol Blood Marrow Transplant. 2014;20:1301-1306. doi: 10.1016/j.bbmt.2014.06.004
111. Kneteman NM, Lakey JR, Wagner T, Finegood D. The metabolic impact of rapamycin (sirolimus) in chronic canine islet graft recipients. Transplantation. 1996;61:1206-1210.
112. Tran CM, Mukherjee S, Ye L, et al. Rapamycin blocks induction of the thermogenic program in white adipose tissue. Diabetes. 2016. doi: 10.2337/db15-0502
113. Bouchie A, DeFrancesco L. Nature Biotechnology's academic spinouts of 2014. Nat Biotechnol. 2015;33:247-255. doi: 10.1038/nbt.3163
114. Fok WC, Chen Y, Bokov A, et al. Mice fed rapamycin have an increase in lifespan associated with major changes in the liver transcriptome. PLoS One. 2014;9:e83988. doi: 10.1371/journal.pone.0083988
115. Hernando E, Charytonowicz E, Dudas ME, Menendez S, Matushansky I, Mills J, et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med. 2007;13:748-753. doi: 10.1038/nm1560
116. Anisimov VN, Zabezhinski MA, Popovich IG, et al. Rapamycin extends maximal lifespan in cancer-prone mice. Am J Pathol. 2010;176:2092-2097. doi: 10.4161/cc.10.24.18486
117. Bhattacharya A, Bokov A, Muller FL, et al. Dietary restriction but not rapamycin extends disease onset and survival of the H46R/H48Q mouse model of ALS. Neurobiol Aging. 2012;33:1829-1832. doi: 10.1016/j.neurobiolaging.2011.06.002.
118. Komarova EA, Antoch MP, Novototskaya LR, et al. Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/- mice. Aging. 2012;4:709-714.
119. Comas M, Toshkov I, Kuropatwinski KK, et al. New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53-/- mice by delaying carcinogenesis. Aging. 2012;4:715-722.
120. Ramos FJ, Chen SC, Garelick MG, et al. Rapamycin reverses elevated mTORC1 signaling in lamin A/C-deficient mice, rescues cardiac and skeletal muscle function, and extends survival. Sci Transl Med. 2012;4:144ra103. doi: 10.1126/scitranslmed.3003802
121. Livi CB, Hardman RL, Christy BA, et al. Rapamycin extends life span of Rb1+/- mice by inhibiting neuroendocrine tumors. Aging. 2013;5:100-110.
122. Khapre RV, Kondratova AA, Patel S, et al. BMAL1-dependent regulation of the mTOR signaling pathway delays aging. Aging. 2014;6:48-57.
123. Popovich IG, Anisimov VN, Zabezhinski MA, et al. Lifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of rapamycin. Cancer Biol Therapy. 2014;15:586-592. doi: 10.4161/cbt.28164
124. Johnson SC, Yanos ME, Bitto A, et al. Dose-dependent effects of mTOR inhibition on weight and mitochondrial disease in mice. Front Genet. 2015;6:247. doi: 10.3389/fgene.2015.00247
125. Hurez V, Dao V, Liu A, et al. Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune-deficient mice. Aging Cell. 2015;14:945-956. doi: 10.1111/acel.12380
126. Sataranatarajan K, Ikeno Y, Bokov A, et al. Rapamycin increases mortality in db/db mice, a mouse model of type 2 diabetes. J Gerontol A Biol Sci Med Sci. 2015. doi: 10.1093/gerona/glv170